Tumor suppression by apoptotic and anti-angiogenic effects of mortalin-targeting adeno-oncolytic virus

Journal of Gene Medicine

Volumn 12, Issue 7, 2010, Pages 586-595

  Yoo, Ji Young ^a   Ryu, Jihoon ^a   Gao, Ran ^b   Yaguchi, Tomoko ^b   Kaul, Sunil C ^b   Wadhwa, Renu ^b   Yun, Chae Ok ^a  

^a Yonsei University College of Medicine   (South Korea)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

Adeno oncolytic viruses; Angiogenesis; Apoptosis; Cancer therapy; Mortalin; siRNA

Indexed keywords

CHAPERONE; MORTALIN; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; HEAT SHOCK PROTEIN 70; ONCOLYTIC VIRUS;

ADENOVIRUS; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER MODEL; CARCINOGENESIS; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME REACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULATURE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RNA SEQUENCE; TUMOR XENOGRAFT; ADENOVIRIDAE; ANIMAL; CELL PROTECTION; DRUG SCREENING; GENETIC TRANSFECTION; METABOLISM; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PROCEDURES; TUMOR CELL LINE; VASCULARIZATION;

ADENOVIRIDAE; ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CYTOPROTECTION; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MICE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 77955639966     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1471     Document Type: Article

References (41)

1. Wadhwa R, Kaul SC, Ikawa Y, Sugimoto Y. Identification of a novel member of mouse hsp70 family. Its association with cellular mortal phenotype. J Biol Chem 1993; 268: 6615-6621.
2. Kaul SC, Deocaris CC, Wadhwa R. Three faces of mortalin: a housekeeper, guardian and killer. Exp Gerontol 2007; 42: 263-274.
3. Wadhwa R, Kaul SC, Mitsui Y, Sugimoto Y. Differential subcellular distribution of mortalin in mortal and immortal mouse and human fibroblasts. Exp Cell Res 1993; 207: 442-448.
4. Wadhwa R, Sugihara T, Yoshida A, et al. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res 2000; 60: 6818-6821.
5. Nakabayashi K, Ogata T, Fujii M, et al. Decrease in amplified telomeric sequences and induction of senescence markers by introduction of human chromosome 7 or its segments in SUSM-1. Exp Cell Res 1997; 235: 345-353. (Pubitemid 27398392)
6. Kaul SC, Duncan EL, Englezou A, et al. Malignant transformation of NIH3T3 cells by overexpression of mot-2 protein. Oncogene 1998; 17: 907-911.
7. Takano S, Wadhwa R, Yoshii Y, Nose T, Kaul SC, Mitsui Y. Elevated levels of mortalin expression in human brain tumors. Exp Cell Res 1997; 237: 38-45. (Pubitemid 27528026)
8. Dundas SR, Lawrie LC, Rooney PH, Murray GI. Mortalin is overexpressed by colorectal adenocarcinomas and correlates with poor survival. J Pathol 2005; 205: 74-81.
9. Wadhwa R, Takano S, Kaur K, et al. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J Cancer 2006; 118: 2973-2980.
10. Shi M, Jin J, Wang Y, et al. Mortalin: a protein associated with progression of Parkinson disease? J Neuropathol Exp Neurol 2008; 67: 117-124.
11. Yi X, Luk JM, Lee NP, et al. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics 2008; 7: 315-325. (Pubitemid 351298446)
12. Walker C, Bottger S, Low B. Mortalin-based cytoplasmic sequestration of p53 in a nonmammalian cancer model. Am J Pathol 2006; 168: 1526-1530.
13. Ma Z, Izumi H, Kanai M, Kabuyama Y, Ahn NG, Fukasawa K. Mortalin controls centrosome duplication via modulating centrosomal localization of p53. Oncogene 2006; 25: 5377-5390.
14. Kanai M, Ma Z, Izumi H, et al. Physical and functional interaction between mortalin and Mps1 kinase. Genes Cells 2007; 12: 797-810.
15. Shin BK, Wang H, Yim AM, et al. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem 2003; 278: 7607-7616.
16. Cussac D, Pichereaux C, Colomba A, et al. Proteomic analysis of anaplastic lymphoma cell lines: identification of potential tumour markers. Proteomics 2006; 6: 3210-3222.
17. Flotte TR. Gene therapy: the first two decades and the current state-of-the-art. J Cell Physiol 2007; 213: 301-305.
18. Crompton AM, Kirn DH. From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr Cancer Drug Targets 2007; 7: 133-139.
19. Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. J Pathol 2006; 208: 299-318.
20. Davydova J, Le LP, Gavrikova T, Wang M, Krasnykh V, Yamamoto M. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment. Cancer Res 2004; 64: 4319-4327.
21. Nagi P, Vickers SM, Davydova J, et al. Development of a therapeutic adenoviral vector for cholangiocarcinoma combining tumor-restricted gene expression and infectivity enhancement. J Gastrointest Surg 2003; 7: 364-371. (Pubitemid 36875774)
22. Guo ZS, Thorne, SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 2008; 1785: 217-231.
23. Lee H, Kim J, Lee B, et al. Oncolytic potential of E1B 55 kDa-deleted YKL-1 recombinant adenovirus: correlation with p53 functional status. Int J Cancer 2000; 88: 454-463.
24. Kim J, Kim JH, Choi KJ, Kim PH, Yun CO. E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects. Hum Gene Ther 2007; 18: 773-786.
25. Miyagishi M, Sumimoto H, Miyoshi H, Kawakami Y, Taira K. Optimization of an siRNA-expression system with an improved hairpin and its significant suppressive effects in mammalian cells. J Gene Med 2004; 6: 715-723. (Pubitemid 40228087)
26. Miyagishi M, Taira K. Strategies for generation of an siRNA expression library directed against the human genome. Oligonucleotides 2003; 13: 325-333. (Pubitemid 38404817)
27. Kim E, Kim JH, Shin HY, et al. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 2003; 14: 1415-1428.
28. Yoo JY, Kim JH, Kwon YG, et al. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther 2007; 15: 295-302.
29. Shiota M, Ikeda Y, Kaul Z, Itadani J, Kaul SC, Wadhwa R. Internalizing antibody-based targeted gene delivery for human cancer cells. Hum Gene Ther 2007; 18: 1153-1160.
30. Wadhwa R, Takano S, Robert M, et al. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. J Biol Chem 1998; 273: 29586-29591.
31. Mosser DD, Morimoto RI. Molecular chaperones and the stress of oncogenesis. Oncogene 2004; 23: 2907-2918.
32. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 2006; 5: 2592-2601.
33. Sliutz G, Karlseder J, Tempfer C, Orel L, Holzer G, Simon MM. Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy. BrJ Cancer 1996; 74: 172-177.
34. Kaul SC, Aida S, Yaguchi T, Kaur K, Taira K, Wadhwa R. Activation of wild type p53 function by its mortalin-binding cytoplasmically localizing carboxy-terminus peptides. J Biol Chem 2005; 280: 39373-39379.
35. Kaul SC, Takano S, Reddel RR, Mitsui Y, Wadhwa R. Transcriptional inactivation of p53 by deletions and single amino acid changes in mouse mot-1 protein. Biochem Biophys Res Commun 2000; 279: 602-606.
36. Bottger S, Jerszyk E, Low B, Walker C. Genotoxic stress-induced expression of p53 and apoptosis in leukemic clam hemocytes with cytoplasmically sequestered p53. Cancer Res 2008; 68: 777-782. (Pubitemid 351206754)
37. Young JC, Agashe VR, Siegers K, Hartl FU. Pathways of chaperone-mediated protein folding in the cytosol. Nat Rev Mol Cell Biol 2004; 5: 781-791.
38. Daugaard M, Rohde M, Jaattela M. The heat shock protein 70 family: highly homologous proteins with overlapping and distinct functions. FEBS Lett 2007; 581: 3702-3710.
39. Morishima Y, Murphy PJ, Li DP, Sanchez ER, Pratt WB. Stepwise assembly of a glucocorticoid receptor. hsp90 heterocomplex resolves two sequential ATP-dependent events involving first hsp70 and then hsp90 in opening of the steroid binding pocket. J Biol Chem 2000; 275: 18054-18060.
40. Maloney A, Clarke PA, Naaby-Hansen S, et al. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2007; 67: 3239-3253. (Pubitemid 46724862)
41. Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008; 14: 250-262.